NanoViricides Gets National Ethics Committee Approval For Phase II Clinical Study Of NV-387 Oral Gummies To Treat Current Bundibugyo Ebolavirus In Congo

Loading news article.

NanoViricides Gets National Ethics Committee Approval For Phase II Clinical Study Of NV-387 Oral Gummies To Treat Current Bundibugyo Ebolavirus In Congo | WAPE

NanoViricides Gets National Ethics Committee Approval For Phase II Clinical Study Of NV-387 Oral Gummies To Treat Current Bundibugyo Ebolavirus In Congo

Article summary

Related companies

Comments —